Impact of Delayed Time to Treatment on Visual Outcomes in Neovascular AMD Data From the HARBOR Study

Impact of Delayed Time to Treatment on Visual Outcomes in Neovascular AMD : Data From the HARBOR Study

Copyright 2021, SLACK Incorporated.

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 52(2021), 2 vom: 01. Feb., Seite 62-69
1. Verfasser: Goldberg, Roger A (VerfasserIn)
Weitere Verfasser: Hill, Lauren F, Davis, Tatiana, Ruiz, Carlos Quezada
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Angiogenesis Inhibitors Vascular Endothelial Growth Factor A Ranibizumab ZL1R02VT79
Beschreibung
Zusammenfassung:Copyright 2021, SLACK Incorporated.
BACKGROUND AND OBJECTIVE: To determine the potential impact on visual outcomes of delayed treatment initiation in patients with neovascular age-related macular degeneration (nAMD)
PATIENTS AND METHODS: Post hoc analysis of anti-vascular endothelial growth factor treatment-naïve patients with nAMD from HARBOR. Time to treatment was defined as first ranibizumab injection date minus screening date. Comparisons were made between the prompt (≤ 6 days) versus delayed (> 10 days) treatment groups. Main outcome measures were best-corrected visual acuity (BCVA) change over time, BCVA, number of ranibizumab injections, and proportion of 3-line gainers/losers
RESULTS: In HARBOR, more than 50% of patients received their first injection within 7 days of screening, with mean (median) time to treatment of 4.6 (5) and 15.9 (14) days for the prompt and delayed treatment groups, respectively. Mean (95% confidence interval [CI]) BCVA change from baseline to Month 24 was 9.1 (7.4-10.8) and 8.8 (6.7-10.8) Early Treatment Diabetic Retinopathy Study letters in the prompt (n = 395) and delayed (n = 230) treatment groups, respectively. Mean (95% CI) total number of ranibizumab injections for the as-needed arms was 12.4 (11.6-13.3) and 11.4 (10.3-12.4) for the prompt and delayed treatment groups, respectively
CONCLUSION: In HARBOR, time from screening to first ranibizumab injection did not seem to significantly affect mean BCVA change or number of injections. [Ophthalmic Surg Lasers Imaging Retina. 2021;52:62-69.]
Beschreibung:Date Completed 24.11.2021
Date Revised 24.11.2021
published: Print
Citation Status MEDLINE
ISSN:2325-8179
DOI:10.3928/23258160-20210201-02